Janux Therapeutics (NASDAQ:JANX) Stock Price Target Raised at Wedbush

Janux Therapeutics (NASDAQ:JANX) had its price objective upped by Wedbush from $36.00 to $40.00 in a research note published on Friday,Benzinga reports. They currently have an outperform rating on the stock.

JANX has been the topic of several other reports. Wolfe Research upgraded Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 price target on the stock in a research report on Monday, August 24th. HC Wainwright reaffirmed a “buy” rating on shares of Janux Therapeutics in a report on Monday, October 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Friday, October 16th. Guggenheim reduced their price target on shares of Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Finally, Barclays lifted their price objective on Janux Therapeutics from $14.00 to $15.00 and gave the company an “underweight” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Janux Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $36.92.

Janux Therapeutics Stock Performance

JANX stock traded up $1.57 during midday trading on Friday, reaching $17.63. 852,234 shares of the company’s stock traded hands, compared to its average volume of 769,690. The company has a 50-day moving average price of $17.49 and a two-hundred day moving average price of $15.42. Janux Therapeutics has a 52 week low of $12.12 and a 52 week high of $35.34. The firm has a market capitalization of $1.08 billion, a PE ratio of -11.09 and a beta of 2.44.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.13. The company had revenue of $9.29 million during the quarter, compared to analysts’ expectations of $8.03 million. As a group, analysts predict that Janux Therapeutics will post -1.70 EPS for the current fiscal year.

Institutional Trading of Janux Therapeutics

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Janux Therapeutics in the second quarter worth approximately $94,228,000. Bank of America Corp DE bought a new position in Janux Therapeutics during the second quarter valued at approximately $13,985,000. Nantahala Capital Management LLC purchased a new position in shares of Janux Therapeutics during the second quarter worth approximately $12,440,279. Irenic Capital Management LP purchased a new position in shares of Janux Therapeutics during the first quarter worth approximately $10,645,000. Finally, Algert Global LLC lifted its holdings in shares of Janux Therapeutics by 150.5% in the 2nd quarter. Algert Global LLC now owns 1,110,889 shares of the company’s stock worth $17,063,000 after acquiring an additional 667,492 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Key Stories Impacting Janux Therapeutics

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $40 from $36 and reiterated its outperform rating, implying substantial upside from the cited $17.63 share price. Wedbush raises Janux price target
• Positive Sentiment: Truist raised its target to $27 from $26 and maintained a buy rating, signaling continued confidence in JANX. Truist analyst recommendations
• Positive Sentiment: Janux reported a third-quarter loss of $0.34 per share, narrower than analysts’ expected loss of $0.45–$0.47. Revenue of $9.29 million also exceeded the $8.03 million estimate. The results beat expectations, although the company remained loss-making. Janux third-quarter 2026 results
• Neutral Sentiment: Janux said it dosed the first patient in the Phase 1 study of JANX013 in combination with JANX007, marking progress in its clinical pipeline; the update does not establish how the treatment will perform. Janux business highlights
• Negative Sentiment: Barclays raised its target only to $15 from $14 but kept an underweight rating, placing its target below the cited share price and underscoring a bearish view that contrasts with other analysts. Barclays analyst recommendations

About Janux Therapeutics

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.